logo-loader
viewN4 Pharma PLC

N4 Pharma's Nuvec platform 'on a clear path' towards clinical trials

N4 Pharma PLC (LON:N4P) CEO Nigel Theobald speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019.

He says it's been an incredibly active period for them where, among a number of developments, they've confirmed that Nuvec® works for both DNA and mRNA delivery.

Quick facts: N4 Pharma PLC

Price: 4.75 GBX

AIM:N4P
Market: AIM
Market Cap: £7.23 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen CEO details expansion of key coronavirus trial to patients in home

Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the...

9 hours, 37 minutes ago

2 min read